Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Alnylam Pharmaceuticals, Inc. (NQ: ALNY)
28.98 USD  +0.92 (+3.28%)
Official Closing Price  /  Updated: 8:10 PM EDT, May 24, 2013  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 0
Open 28.84
Bid (Size) 28.98 (1700)
Ask (Size) 29.00 (5000)
Prev. Close 28.06
Today's Range 28.47 - 29.07
52wk Range 9.784 - 29.00
Shares Outstanding 62,171,037
Dividend Yield N/A
Top News
More News
UPDATE: Deutsche Bank Initiates Coverage on Alnylam Pharmaceuticals with Buy Rating, $40 PT on Significant Long-Term Value Potential
May 24, 2013
In a report published Friday, Deutsche Bank analyst Alethia Young initiated coverage on Alnylam Pharmaceuticals (NASDAQ: ALNY ) with a Buy rating and $40.00 price target. In the report, Young noted,... Read More
category Deutsche Bank , Benzinga , ALNY , and 3 more.
from Latest Articles from Benzinga.com
Benzinga's Top Initiations
May 24, 2013
Deutsche Bank initiated coverage on shares of Alnylam Pharmaceuticals (NASDAQ: ALNY ) with a “buy” rating. The target price for Alnylam Pharmaceuticals is set to $40. Alnylam's stock closed at $28.06... Read More
category Benzinga , CACC , Initiation , and 5 more.
from Latest Articles from Benzinga.com

More News
Read More
Deutsche Bank Starts Alnylam Pharmaceuticals (ALNY) at Buy
May 24, 2013
from StreetInsider.com News Articles
Alnylam Pharmaceuticals: The Winning Streak Continues (ALNY)
May 22, 2013
from Comtex SmarTrend® News Briefs
Alnylam to Webcast Presentation at Deutsche Bank 38th Annual dbAccess Health Care Conference
May 21, 2013
from Business Wire News Releases
Investors Begin To Realize RNA’s Potential
May 21, 2013
from ACCESSWIRE
Alnylam Pharmaceuticals Has Returned 47.2% Since SmarTrend Recommendation (ALNY)
May 21, 2013
from Comtex SmarTrend® News Briefs
Post Earnings Update: Alnylam Pharmaceuticals Has Climbed 15.8% Higher in Past 2 Weeks (ALNY)
May 20, 2013
from Comtex SmarTrend® News Briefs
Alnylam (ALNY) Updates on Preclinical Data for RNAi Program Targeting ALAS-1
May 17, 2013
from StreetInsider.com News Articles
Alnylam Presents Key Pre-Clinical Proof-of-Concept Data for ALN-AS1, an RNAi Therapeutic Targeting Aminolevulinate Synthase-1 (ALAS-1) for the Treatment of Porphyria
May 17, 2013
from Business Wire News Releases
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here